{"id":"NCT00322452","sponsor":"AstraZeneca","briefTitle":"First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia","officialTitle":"Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2008-04","completion":"2010-06","firstPosted":"2006-05-08","resultsPosted":"2010-05-17","lastUpdate":"2013-11-07"},"enrollment":1329,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Gefitinib","otherNames":["Iressa","ZD1839"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.","primaryOutcome":{"measure":"Median Progression Free Survival (PFS) in Months","timeFrame":"Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).","effectByArm":[{"arm":"Gefitinib","deltaMin":5.7,"sd":null},{"arm":"Carboplatin/Paclitaxel","deltaMin":5.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":56,"countries":["China","Hong Kong","Indonesia","Japan","Malaysia","Philippines","Singapore","Taiwan","Thailand"]},"refs":{"pmids":["31920008","28212993","24361280","23540718","22897752","19692680"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":110,"n":607},"commonTop":["Rash","Diarrhoea","Alopecia","Nausea","Anorexia"]}}